BioTech Medics, Inc. to Acquire Waterview Office Complex-Dallas

DALLAS, Feb. 13  /PRNewswire-FirstCall/ -- BioTech Medics, Inc., (OTC Pink Sheets: BTMD) announces that it has entered into a Letter of Intent with the Owners to acquire nearly 6 acres and over 90,640 sq. ft. of office complex known as The Waterview Complex at 9535 Forest, Dallas, Texas.

Keith Houser, CEO has stated: "We continue our pledge to our shareholders to add significant assets to the Company through mergers and acquisitions. This property when fully leased appraises at almost $12 million.  This will give BTMD a permanent location for our international headquarters and our Pain Management & Wellness Center in North Dallas. Due to our prior merger with FHJ and the 5 SHBAN solution patent acquisition and the pending merger acquisition with Harwood Enterprises Worldwide Nutraceutical Company, BTMD ultimately plans on occupying up to 20,000 square feet of the Waterview building. Existing tenants and future ancillary tenants will be completing the occupancy over the next year."

BioTech has also entered into an agreement with a private real estate investment group who will be providing some equity and bank financing for the acquisition. Closing is expected on or about April 10, 2006.

BioTech Medics is a distributor for the NeuroLase Therapeutic Medical Laser.  It owns a Pain Management and Wellness Center in Dallas and plans on opening more this year nationwide.  Check out BTMD's web site at: http://www.biotechmedics.com/ .

   Contact:  Keith Houser
   Phone [phone]

  Safe Harbor for Forward-Looking Statements.


This press contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 (the "Act"). In Particular, when used in the preceding discussion, the words "plan," "confident that," "believe," "scheduled," "expect," or "intend to," and similar conditional expressions are intended to identify forward-looking statements within the meaning of the Act and are subject to the safe harbor created by the Act. Such statements are subject to certain risks and uncertainties and actual results could differ materially from those expressed in any of the forward-looking statements. Such risks and uncertainties include, but are not limited to, the ability of the company to complete the planned bridge financing, market conditions, the general acceptance of the Company's products and technologies, competitive actors, timing, and other risks. 

DATASOURCE: BioTech Medics, Inc.



CONTACT:  Keith Houser of BioTech Medics, Inc., [phone]



Web site:  http://www.biotechmedics.com/ 

Copyright